2m 2m 2m 2m 2m 2m 2m
Neurocrine Biosc (NBIX)
NASDAQ
$155.28+$2.71 (+1.78%)
Price as of Aug 21, 2026 7:47 PM EDT- $15.5BMarket Cap
- 12.66%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
Neurocrine Biosc (NBIX)
$155.28+$2.71 (+1.78%)
NBIX | vs History | vs S&P 500 | |
|---|---|---|---|
General Statistics | |||
Latest Close | $152.57 | ||
Change | -$0.36 (-0.24%) | ||
Open | $153.13 | ||
High | $155.26 | ||
Low | $152.51 | ||
Previous Close | $152.93 | ||
Volume | 1,227,625 | ||
30-Day Average Volume | 1,419,606 | ||
1-Week Change | -0.10% | ||
1-Month Change | -14.79% | ||
1-Year Change | 12.66% | ||
3-Year Change | 40.85% | ||
5-Year Change | 66.29% | ||
Fundamentals | |||
Shares Outstanding | 101.6M | ||
Total Assets | $5.4B | ||
Market Cap | $15.5B | ||
Enterprise Value | $15.2B | ||
Period: QTR TTM FY | |||
Revenue | $954.3M | ||
Net Income | $144.4M | ||
Free Cash Flow | $128.6M | ||
EBIT | $165.1M | ||
EBITDA | $181.5M | ||
Net Working Capital | $763.0M | ||
EPS | $1.39 | ||
Enterprise Value/EBITDA | 84 | ||
Enterprise Value/Revenue | 16 | ||
P/B | 4 | ||
P/E | 110 | ||
PEG | -4 | ||
Price/Free Cash Flow | 121 | ||
Price/Operating Cash Flow | 114 | ||
Dividends & Splits | |||
Forward Annual Dividend Yield | N/A | ||
Trailing Annual Dividend Yield | N/A | ||
Ex-Dividend Date | N/A | ||
Last Split Factor | N/A | ||
Last Split Date | N/A | ||
Earnings & Revenue